tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Loss M et al. Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy. 1996 Transplant. Proc. pmid:8623210
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Harrison DM et al. Reduction in hospital stay after liver transplantation. 1996 Transplant. Proc. pmid:8623451
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Pirenne J et al. Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623472
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
Muraoka K et al. Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. 1996 J. Clin. Invest. pmid:8647935
Kawashima M et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. 1996 Lancet pmid:8898050
Brunke M et al. Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases. 1996 J. Biol. Chem. pmid:8798557
Drake M et al. The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. 1996 Acta Physiol. Scand. pmid:8899062
Zhang Q et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8799169
Spencer DM et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. 1996 Curr. Biol. pmid:8805308
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Ichikawa Y et al. Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. 1996 Int. J. Urol. pmid:8776613
Mugiya S et al. Renal blood flow and serotonin metabolism in tacrolimus treated rats. 1996 Int. J. Urol. pmid:8776615
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Alessiani M et al. Intestinal transplantation with and without the colon in FK 506 immunosuppressed pigs. 1996 Transplant. Proc. pmid:8908021
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Ho S et al. The mechanism of action of cyclosporin A and FK506. 1996 Clin. Immunol. Immunopathol. pmid:8811062
Nishino H et al. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. 1996 J. Chem. Neuroanat. pmid:8811425
Sonatore LM et al. The utility of FK506-binding protein as a fusion partner in scintillation proximity assays: application to SH2 domains. 1996 Anal. Biochem. pmid:8811923
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Guérette B et al. Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. 1996 Muscle Nerve pmid:8965835
Sharkey J et al. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. 1996 Stroke pmid:8969794
Hedayat S et al. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. 1996 J Biopharm Stat pmid:8969977
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
Nishimura Y et al. Whole organ vascularized thymus allografting effectively modulates cardiac rejection. 1996 Transplant. Proc. pmid:8658660
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Watanabe K et al. Immunosuppressive effect of bactobolamine in rat liver allotransplantation. 1996 Transplant. Proc. pmid:8658697
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Cai W et al. Transcription-modulating drugs: mechanism and selectivity. 1996 Curr. Opin. Biotechnol. pmid:8939643
Freiberg RA et al. Specific triggering of the Fas signal transduction pathway in normal human keratinocytes. 1996 J. Biol. Chem. pmid:8940187
Poon M et al. Rapamycin inhibits vascular smooth muscle cell migration. 1996 J. Clin. Invest. pmid:8941644
Rokaw MD et al. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells. 1996 J. Biol. Chem. pmid:8943313
Matsui A et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. 1996 Acta Paediatr Jpn pmid:9002314
Adachi M et al. Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain. 1996 Blood pmid:8943845
DeCenzo MT et al. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. 1996 Protein Eng. pmid:9005438
Przepiorka D et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. 1996 Blood pmid:8943876
Blecher O et al. A novel plant peptidyl-prolyl-cis-trans-isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. 1996 Plant Mol. Biol. pmid:8980498
McCall E et al. Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. 1996 Circ. Res. pmid:8943949
Winkler M et al. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. 1996 Ther Drug Monit pmid:8946659
Thompson PA and Mosley CA Tacrolimus-phenytoin interaction. 1996 Ann Pharmacother pmid:8740340
Christophers E Psoriasis: mechanisms and entry points for possible therapeutic interventions. 1996 Australas. J. Dermatol. pmid:8713012
Alak AM and Lizak P Stability of FK506 in blood samples. 1996 Ther Drug Monit pmid:8721287
Yu C et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. 1996 Bone Marrow Transplant. pmid:8722370
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Small SL et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) 1996 Ann. Neurol. pmid:8871576
Stempfle HU [Osteoporosis following heart transplantation. Pathogenesis and therapy]. 1996 Dtsch. Med. Wochenschr. pmid:8846757
Sadakane Y and Nakashima H Light-induced phase shifting of the circadian conidiation rhythm is inhibited by calmodulin antagonists in Neurospora crassa. 1996 J. Biol. Rhythms pmid:8872595
Akashi T et al. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. 1996 J Pharm Biomed Anal pmid:8851758
Jordan ML et al. The use of tacrolimus in renal transplantation. 1996 World J Urol pmid:8873438
Wada Y et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. 1996 Artif Organs pmid:8853794
Clark W Tacrolimus: immunosuppression following liver and kidney transplant. 1996 J Clin Pharm Ther pmid:8873845
Lochmüller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. 1996 Gene Ther. pmid:8854096
DiMartini AF et al. Prospective study of FK506 side effects: anxiety or akathisia? 1996 Biol. Psychiatry pmid:8874843
Horn F and Gross J A role for calcineurin in Dictyostelium discoideum development. 1996 Differentiation pmid:8855370
Lu YF et al. Calcineurin inhibitors, FK506 and cyclosporin A, suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus. 1996 Brain Res. pmid:8874888
Barkholt LM et al. Epstein-Barr virus DNA in serum after liver transplantation--surveillance of viral activity during treatment with different immunosuppressive agents. 1996 Transpl. Int. pmid:8875785
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Morris-Stiff G et al. Haemolytic uraemic syndrome associated with OKT3. 1996 Transpl. Int. pmid:8875800
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Dhar DK et al. FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. 1996 J. Surg. Res. pmid:8592405
Kay JE Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. 1996 Biochem. J. pmid:8670043
Schmaldienst S and Horl WH Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. 1996 Nephrol. Dial. Transplant. pmid:8672015
Taylor PJ et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. 1996 Clin. Chem. pmid:8595724
Hartley AD et al. cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi. 1996 Mol. Gen. Genet. pmid:8709962
Tokime T et al. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. 1996 Neurosci. Lett. pmid:8710192
Dan Y et al. IL-3 augments TCR-mediated responses of type 2 CD4 T cells. 1996 J. Immunol. pmid:8598473
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Lampen A et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. 1996 Br. J. Pharmacol. pmid:8732283
Beretta L et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. 1996 EMBO J. pmid:8599949
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635